Translator Disclaimer
17 February 2012 Application of Metabolic PET Imaging in Radiation Oncology
Aizhi Zhu, David M. Marcus, Hui-Kuo G. Shu, Hyunsuk Shim
Author Affiliations +
Abstract

Positron emission tomography (PET) is a noninvasive imaging technique that provides functional or metabolic assessment of normal tissue or disease conditions and is playing an increasing role in cancer radiotherapy planning. 18F-Fluorodeoxyglucose PET imaging (FDG-PET) is widely used in the clinic for tumor imaging due to increased glucose metabolism in most types of tumors; its role in radiotherapy management of various cancers is reviewed. In addition, other metabolic PET imaging agents at various stages of preclinical and clinical development are reviewed. These agents include radiolabeled amino acids such as methionine for detecting increased protein synthesis, radiolabeled choline for detecting increased membrane lipid synthesis, and radiolabeled acetate for detecting increased cytoplasmic lipid synthesis. The amino acid analogs choline and acetate are often more specific to tumor cells than FDG, so they may play an important role in differentiating cancers from benign conditions and in the diagnosis of cancers with either low FDG uptake or high background FDG uptake. PET imaging with FDG and other metabolic PET imaging agents is playing an increasing role in complementary radiotherapy planning.

Aizhi Zhu, David M. Marcus, Hui-Kuo G. Shu, and Hyunsuk Shim "Application of Metabolic PET Imaging in Radiation Oncology," Radiation Research 177(4), 436-448, (17 February 2012). https://doi.org/10.1667/RR2702.1
Received: 13 June 2011; Accepted: 1 August 2011; Published: 17 February 2012
JOURNAL ARTICLE
13 PAGES


Share
SHARE
RIGHTS & PERMISSIONS
Get copyright permission
Back to Top